CytomX Therapeutics Inc.

Contributing Author

Recent Articles by CytomX Therapeutics Inc.

Jun-03	CytomX Announces Expansion of Strategic Research Collaboration with Regeneron in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer CTMX GlobeNewswire
May-21	CytomX Therapeutics to Present at Upcoming June Investor Conferences CTMX GlobeNewswire
May-18	CytomX Therapeutics Appoints Mamata Gokhale, Ph.D., RAC, as Senior Vice President of Regulatory Affairs CTMX GlobeNewswire
May-07	CytomX Therapeutics Announces Q1 2026 Financial Results and Provides Business Update CTMX GlobeNewswire
Apr-30	CytomX Therapeutics to Report First Quarter 2026 Financial Results on May 7, 2026 CTMX GlobeNewswire
Mar-17	CytomX Therapeutics Announces Pricing of $250 Million Offering of Common Stock and Pre-Funded Warrants CTMX -19.27% GlobeNewswire
Mar-16	CytomX Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants CTMX +44.23% GlobeNewswire
Mar-16	CytomX Therapeutics Announces 2025 Financial Results and Provides Business Update CTMX +44.23% GlobeNewswire
Mar-16	CytomX's Varsetatug Masetecan (EpCAM PROBODY ADC) Continues to Demonstrate Positive Data Supporting Potential as a New Treatment Option in Late-Line Colorectal Cancer CTMX +44.23% GlobeNewswire
Mar-04	CytomX Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on March 16, 2026 CTMX +5.41% GlobeNewswire
Feb-04	CytomX Therapeutics to Present at Upcoming February Conferences CTMX -6.59% GlobeNewswire
Jan-08	CytomX Therapeutics Announces Business Update and Company Milestones for 2026 CTMX GlobeNewswire
Nov-25	CytomX Therapeutics to Present at Upcoming December Investor Conferences CTMX GlobeNewswire
Nov-13	CytomX Therapeutics to Present at the Jefferies London Healthcare Conference CTMX -8.75% GlobeNewswire
Nov-06	CytomX Therapeutics Announces Third Quarter 2025 Financial Results and Provides Business Update CTMX -13.60% CTMX GlobeNewswire
Nov-04	CytomX Therapeutics to Present CX-801 Phase 1 Monotherapy Biomarker Data at the Society for Immunotherapy of Cancer (SITC) Annual Meeting CTMX GlobeNewswire
Oct-30	CytomX Therapeutics to Report Third Quarter 2025 Financial Results on November 6, 2025 CTMX GlobeNewswire
Oct-20	CytomX Therapeutics Appoints Rachael Lester as Chief Business Officer CTMX +16.87% GlobeNewswire
Aug-28	CytomX Therapeutics to Present at Upcoming September Investor Conferences CTMX GlobeNewswire
Aug-13	CytomX Therapeutics Provides Update on CX-2051 Phase 1 Study CTMX GlobeNewswire
Aug-07	CytomX Therapeutics Announces Second Quarter 2025 Financial Results and Provides Business Update CTMX +11.90% CTMX GlobeNewswire
Jul-31	CytomX Therapeutics to Report Second Quarter 2025 Financial Results on August 7, 2025 CTMX -5.60% GlobeNewswire
May-29	CytomX Therapeutics to Present at the Jefferies Global Healthcare Conference CTMX GlobeNewswire
May-19	CytomX Therapeutics Announces First Patient Dosed in Combination Arm of Phase 1 Study of CX-801 plus KEYTRUDA (pembrolizumab) in Patients with Metastatic Melanoma CTMX GlobeNewswire
May-12	CytomX Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock CTMX +129.43% GlobeNewswire
May-12	CytomX Announces Positive Interim Data From Phase 1 Dose Escalation Study of EpCAM Antibody Drug Conjugate (CX-2051) Candidate in Patients with Advanced Colorectal Cancer (CRC) CTMX +129.43% GlobeNewswire
May-12	CytomX Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update CTMX +129.43% GlobeNewswire
May-05	CytomX Therapeutics to Report First Quarter 2025 Financial Results on May 12, 2025 CTMX +19.85% GlobeNewswire

CytomX Therapeutics Inc.

Recent Articles by CytomX Therapeutics Inc.

Upgrade your Finviz experience